In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
After finishing at $71.5 in the prior trading day, Tarsus Pharmaceuticals Inc (NASDAQ: TARS) closed at $68.2, down -4.62%. In other words, the price has decreased by -$4.62 from its previous closing price. On the day, 0.96 million shares were traded. TARS stock price reached its highest trading level at $71.9499 during the session, while it also had its lowest trading level at $67.5.
Ratios:
Our goal is to gain a better understanding of TARS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.25 and its Current Ratio is at 4.29. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.25.
On November 20, 2023, Goldman started tracking the stock assigning a Neutral rating and target price of $19.Goldman initiated its Neutral rating on November 20, 2023, with a $19 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 24 ’25 when Azamian Bobak R. sold 6,000 shares for $55.37 per share. The transaction valued at 332,220 led to the insider holds 812,106 shares of the business.
Bobak Azamian Living Trust bought 6,000 shares of TARS for $332,208 on Sep 24 ’25. On Sep 08 ’25, another insider, LINK WILLIAM J PHD, who serves as the Director of the company, sold 27,116 shares for $57.00 each. As a result, the insider received 1,545,612 and left with 143,332 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TARS now has a Market Capitalization of 2895028736 and an Enterprise Value of 2709611520. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.29 while its Price-to-Book (P/B) ratio in mrq is 8.64. Its current Enterprise Value per Revenue stands at 9.169 whereas that against EBITDA is -28.103.
Stock Price History:
The Beta on a monthly basis for TARS is 0.76, which has changed by 0.5281043 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, TARS has reached a high of $76.81, while it has fallen to a 52-week low of $38.51. The 50-Day Moving Average of the stock is 9.37%, while the 200-Day Moving Average is calculated to be 35.25%.
Shares Statistics:
The stock has traded on average 664.75K shares per day over the past 3-months and 510750 shares per day over the last 10 days, according to various share statistics. A total of 42.45M shares are outstanding, with a floating share count of 38.61M. Insiders hold about 8.53% of the company’s shares, while institutions hold 108.89% stake in the company. Shares short for TARS as of 1760486400 were 7025255 with a Short Ratio of 10.57, compared to 1757894400 on 7634147. Therefore, it implies a Short% of Shares Outstanding of 7025255 and a Short% of Float of 17.21.
Earnings Estimates
Investors are keenly observing as 1.0 analysts analyze and rate. The current performance of Tarsus Pharmaceuticals Inc (TARS) in the stock market.The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.24 and low estimates of -$0.24.
Analysts are recommending an EPS of between -$1.39 and -$1.39 for the fiscal current year, implying an average EPS of -$1.39. EPS for the following year is $0.75, with 2.0 analysts recommending between $0.91 and $0.59.
Revenue Estimates
5 analysts predict $143.6M in revenue for. The current quarter. It ranges from a high estimate of $145.08M to a low estimate of $142.76M. As of. The current estimate, Tarsus Pharmaceuticals Inc’s year-ago sales were $66.41MFor the next quarter, 5 analysts are estimating revenue of $148.83M. There is a high estimate of $155M for the next quarter, whereas the lowest estimate is $144.57M.
A total of 7 analysts have provided revenue estimates for TARS’s current fiscal year. The highest revenue estimate was $444.77M, while the lowest revenue estimate was $442.45M, resulting in an average revenue estimate of $443.22M. In the same quarter a year ago, actual revenue was $182.95MBased on 6 analysts’ estimates, the company’s revenue will be $674.11M in the next fiscal year. The high estimate is $776.67M and the low estimate is $604.3M.
